Next Generation News and Research

RSS

Life Technologies introduces three next generation genetic engineering kits

Life Technologies Corporation today announced the launch of three next generation GeneArt genetic engineering kits that allow molecular and synthetic biologists unprecedented speed, flexibility, precision, and efficiency for the seamless cloning, assembly, and editing of genetic material.

19 Jun 2012

movin' mania, a community wide effort to address childhood obesity

Bon Secours Virginia Health System has launched movin' mania, a community wide effort to address childhood obesity, the leading health concern for children today. The health system gathered community partners and hundreds of area school children for a kickoff rally Thursday at the Science Museum of Virginia.

18 Jun 2012

FDA clears LensAR Laser System for anterior capsulotomy

LensAR Inc., developer of the LensAR Laser System for cataract surgery, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the company's next-generation commercial system, for use in anterior capsulotomy, with and without laser phacofragmentation during cataract surgery.

18 Jun 2012

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

18 Jun 2012

LFA announces 2012 Gina M. Finzi Memorial Student Fellowship Program grantees

The Lupus Foundation of America (LFA) is pleased to announce the 2012 Gina M. Finzi Memorial Student Fellowship Program grantees. This unique program, established more than 25 years ago by former LFA President Dr. Sergio Finzi in honor of his daughter Gina who passed away from lupus, seeks to cultivate an interest in lupus research among young scientists by funding basic, clinical, translational, epidemiological, and behavioral research studies under the supervision of an established investigator.

15 Jun 2012

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.

15 Jun 2012

Sanovas receives U.S. patent allowance for microsurgical lung cancer technology

Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities.

15 Jun 2012

First inventory of microbial diversity in the world's oceans

The landmark publication this week of a "map" of the bacterial make-up of healthy humans has deep roots in an unexpected place: the ocean.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Chagas disease – ‘the AIDS of the Americas’

A recent editorial published in the Public Library of Science's Neglected Tropical Diseases called Chagas disease, a parasite which kills about 20,000 people a year, "the AIDS of the Americas." The disease can be transferred to a child from its mother or by blood transfusions. About 20 percent of those infected can develop life-threatening illness that includes enlarged hearts or intestines, and the drugs used today to treat the disease can take months to work.

12 Jun 2012

Syapse introduces Discovery app to organize R&D data and processes

Syapse announced today the commercial launch of Discovery, its cloud-based application for making omics data actionable in clinical research and development. Discovery combines a powerful platform for aggregating and structuring biomedical data with intuitive data mining, workflow, and reporting features, enabling biopharma and diagnostics companies to leverage the increasing amount of data generated by advanced omics technologies such as next-generation sequencing.

12 Jun 2012

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."

12 Jun 2012

Viewpoints: Hoping that 'Gang of Six' will cut fiscal deal; Sen. Alexander links health law and college tuition increases

The public has a famously low opinion of Congress, even though people tend to hold a less disparaging view of their own representatives. The last two years have been especially tough on the institution's reputation, a response to the body's relentless brinkmanship and paralyzing partisanship in the face of a slow economy. So it is with some trepidation that I throw out a little love for a handful of senators still seeking bipartisan agreement on a plan to bring the federal government back to fiscal responsibility.

11 Jun 2012

Study packs powerful one-two punch in the fight against heart failure

A new study in the journal Circulation packs a powerful one-two punch in the fight against heart failure. The leading blow: Identification of a unique alliance of proteins that plays a major role in the development of the disease. The second but equally powerful hit: Drugs that interfere with this axis already exist.

8 Jun 2012

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

JDRF and BD today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information.

From BD (Becton, Dickinson and Company) 8 Jun 2012

dSarm/Sarm1 gene promotes axon destruction after injury

Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy.

8 Jun 2012

HIV superinfection may be more frequent among general population of Uganda

HIV superinfection, when a person with HIV could acquire a second, new strain of HIV, may occur as often as initial HIV infection in the general population in Uganda, a study suggests.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment of 40 patients in the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

7 Jun 2012

Small stature spinal system announced by K2M

K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced the debut of the MESA® Small Stature Spinal System, a Ø4.5 mm line extension of the company’s revolutionary low profile, zero torque family of products.

6 Jun 2012